Virpax Pharmaceuticals: Virpax Begins IND Enabling Studies of Envelta
WEST CHESTER, PA / ACCESSWIRE / February 23, 2021 / Virpax
® Pharmaceuticals Inc. ( Virpax or the Company ) (NASDAQ:VRPX), today announced that according to the Cooperative Research and Development Agreement ( CRADA ) entered into between Virpax and the National Center for Advancing Translational Sciences ( NCATS ), an institute/center of the National Institutes of Health ( NIH ), U.S. Department of Health and Human Services, the NCATS has begun the Investigational New Drug ( IND ) enabling studies of Envelta for Virpax to support Virpax s future application for clearance from the FDA to initiate its first-in-human ( FIH ) clinical trials.
Anthony P. Mack, Chairman and CEO of Virpax stated, The commencement of these critical pre-clinical studies takes us one step closer to the clinic. Dr. Jeffrey Gudin, principal investigator and co-founder of Virpax, has been working in partnership with the NCATS since we a